Efficacy and safety of biologic agents and tofacitinib in moderate‐to‐severe ulcerative colitis: A systematic overview of meta‐analyses
| Autor: | Pantavou, Katerina, Yiallourou, Anneza I., Piovani, Daniele, Evripidou, Despo, Danese, Silvio, Peyrin-Biroulet, Laurent, Bonovas, Stefanos, Nikolopoulos, Georgios K. |
|---|---|
| Přispěvatelé: | Pantavou, K, Yiallourou, Ai, Piovani, D, Evripidou, D, Danese, S, Peyrin-Biroulet, L, Bonovas, S, Nikolopoulos, Gk, Yiallourou, Anneza I. [0000-0003-1237-1661], Bonovas, Stefanos [0000-0001-6102-6579], Pantavou, Katerina [0000-0002-9176-4369], Piovani, Daniele [0000-0002-1414-6639], Danese, Silvio [0000-0001-7341-1351], Nikolopoulos, Georgios K. [0000-0002-3307-0246] |
| Rok vydání: | 2019 |
| Předmět: |
Moderate to severe
medicine.medical_specialty Rectum Disease Severity of Illness Index Gastroenterology Inflammatory bowel disease Biological Factors 03 medical and health sciences 0302 clinical medicine Piperidines Internal medicine medicine Humans Pyrroles Molecular Targeted Therapy Colitis Adverse effect Protein Kinase Inhibitors Clinical Trials as Topic Tofacitinib business.industry medicine.disease Ulcerative colitis digestive system diseases Pyrimidines Treatment Outcome medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Colitis Ulcerative Drug Therapy Combination 030211 gastroenterology & hepatology business Biomarkers |
| Zdroj: | United European Gastroenterology Journal |
| ISSN: | 2050-6414 2050-6406 |
| DOI: | 10.1177/2050640619883566 |
| Popis: | BackgroundUlcerative colitis (UC) is an inflammatory disease of the colon and rectum. Treatment options include biologics and tofacitinib.ObjectivesWe aim to summarize the evidence on efficacy and safety of biologics and tofacitinib in moderate-to-severe UC.MethodsPubMed, Embase, Scopus, and the Cochrane Library were systematically searched to identify meta-analyses of randomized controlled trials assessing adalimumab, golimumab, infliximab, vedolizumab, and tofacitinib in UC. Efficacy outcomes included induction and maintenance of clinical response, clinical remission and mucosal healing. Safety outcomes included adverse events and serious adverse events.ResultsThe overview involved 31 meta-analyses. All four biologics and tofacitinib were superior to placebo regarding efficacy. Indirect comparisons suggested that infliximab may be better than adalimumab and golimumab to induce clinical response and mucosal healing. Safety analyses indicated no increased rates of adverse events, except for infliximab.ConclusionsBiologics and tofacitinib are efficacious and safe for treating UC. These findings can support clinical decision-making. 7 10 1285 1303 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text